Systemic therapy for metastatic malignant melanoma – from deeply disappointing to bright future?
暂无分享,去创建一个
[1] V. Sondak,et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Grou , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] P. Lorigan,et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Gore,et al. Randomized adjuvant therapy trials in melanoma: surgical and systemic. , 2007, Seminars in oncology.
[4] S. Steinberg,et al. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.
[5] T. Curiel,et al. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. , 2007, Blood.
[6] C. Yunis,et al. Pharmacokinetics of 852A, an Imidazoquinoline Toll‐Like Receptor 7‐Specific Agonist, Following Intravenous, Subcutaneous, and Oral Administrations in Humans , 2007, Journal of clinical pharmacology.
[7] M. Maio,et al. Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications , 2007, Journal of cellular physiology.
[8] Michael L. Wang,et al. Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B‐cell non‐Hodgkin lymphoma , 2007, British journal of haematology.
[9] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[10] J. Hainsworth,et al. A multicenter phase II study of erlotinib and bevacizumab in patients with metastatic melanoma , 2007 .
[11] P. Hwu,et al. A randomized phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM) , 2007 .
[12] R. Gonzalez,et al. Subgroup analysis of efficacy and safety analysis of a randomized, double-blinded controlled phase II study of STA-4783 in combination with paclitaxel in patients with metastatic melanoma , 2007 .
[13] A. Testori,et al. A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results , 2007 .
[14] J. Kirkwood,et al. A phase II study of YM155, a novel survivin suppressant, administered by 168 hour continuous infusion in patients with unresectable stage III or stage IV melanoma , 2007 .
[15] V. Suman,et al. Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma , 2007 .
[16] A. Hauschild,et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma , 2007 .
[17] A. Hauschild,et al. EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial , 2007 .
[18] R. Elashoff,et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites , 2007 .
[19] P. Hersey,et al. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma , 2007 .
[20] C. Soubrane,et al. Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A,C,D) and their receptors (R1, R2, and R3) in advanced melanoma patients , 2007 .
[21] M. Gore,et al. An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma , 2007 .
[22] P. Hwu,et al. Preliminary results from a phase I/II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy , 2007 .
[23] G. Linette,et al. Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma , 2007 .
[24] J. Goodwin,et al. Elderly patients with resected stage II, IIIA non-small cell lung cancer, increased referral rate to medical oncologists, 1992-2002 , 2007 .
[25] L. Mariani,et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Ranson,et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. McArthur,et al. An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma , 2007, Clinical Cancer Research.
[28] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[29] Helen X. Chen,et al. A Randomized Phase 2 Trial of Bevacizumab with or without Daily Low-Dose Interferon Alfa-2b in Metastatic Malignant Melanoma , 2007, Annals of Surgical Oncology.
[30] M. Nicolson,et al. Melanoma incidence and mortality in Scotland 1979–2003 , 2007, British Journal of Cancer.
[31] Robert A. Beckman,et al. Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[32] T. Macdonald,et al. IL-21 Counteracts the Regulatory T Cell-Mediated Suppression of Human CD4+ T Lymphocytes1 , 2007, The Journal of Immunology.
[33] W. Ye,et al. Alum with Interleukin-12 Augments Immunity to a Melanoma Peptide Vaccine: Correlation with Time to Relapse in Patients with Resected High-Risk Disease , 2007, Clinical Cancer Research.
[34] S. Wagner,et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[36] A. Mackensen,et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] H. Pehamberger,et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Wilhelm,et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. , 2006, Seminars in oncology.
[40] Kelly B. Moran,et al. Phase I Trial of Sequential Low-Dose 5-Aza-2′-Deoxycytidine Plus High-Dose Intravenous Bolus Interleukin-2 in Patients with Melanoma or Renal Cell Carcinoma , 2006, Clinical Cancer Research.
[41] M. Ratain,et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.
[42] K. Flaherty,et al. Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma , 2006 .
[43] R. Plummer,et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] J. Sosman,et al. Phase II study of erlotinib given daily for patients with metastatic melanoma (MM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] A. Hauschild,et al. A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] A. Ribas,et al. Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] A. Testori,et al. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] 司履生. Cancer epigenetics , 2006 .
[49] M. Atkins,et al. Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.
[50] L Edler,et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] P. Queirolo,et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[52] J. Sosman,et al. Molecular Targets in Melanoma from Angiogenesis to Apoptosis , 2006, Clinical Cancer Research.
[53] M. Atkins,et al. Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma , 2006, Clinical Cancer Research.
[54] S. Rosenberg,et al. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. , 2006, Blood.
[55] R. Dummer,et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] S. Kim-Schulze,et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] S. Mehrotra,et al. Effect of CD4+CD25+ and CD4+CD25− T Regulatory Cells on the Generation of Cytolytic T Cell Response to a Self but Human Tumor-Associated Epitope In Vitro1 , 2006, The Journal of Immunology.
[58] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[59] B. Comin-Anduix,et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] S. Rosenberg,et al. Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade , 2005, The Journal of Immunology.
[61] E. Gilboa,et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.
[62] Hua Yu,et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.
[63] Jens Eickhoff,et al. Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion , 2005, Clinical Cancer Research.
[64] S. Rosenberg,et al. Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma , 2005, Journal of immunotherapy.
[65] D. Schadendorf,et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] A. Covic,et al. New immunosuppressive therapies in renal transplantation: monoclonal antibodies. , 2005, Journal of nephrology.
[67] S. Rosenberg,et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] A. Hershko,et al. The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle* , 2005, Cell Death and Differentiation.
[69] E. Gelmann,et al. The ubiquitin-proteasome pathway and its role in cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] P. LoRusso,et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma , 2005, Cancer.
[71] P. Julka,et al. Randomised study to access the efficacy of calcitonin in controlling pain in patients of metastatic bone lesions poorly responding to opioids , 2005 .
[72] D. Schadendorf,et al. Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients , 2005 .
[73] M. Gore,et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients , 2005 .
[74] Li Yu,et al. [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.
[75] J. Toyota,et al. The efficacy and safety of thymosin alpha‐1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial , 2005, Journal of viral hepatitis.
[76] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] D. Tuveson,et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.
[78] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[79] P. Laird. Cancer epigenetics. , 2005, Human molecular genetics.
[80] M. Sjogren. Thymalfasin: an immune system enhancer for the treatment of liver disease , 2004, Journal of gastroenterology and hepatology.
[81] P. M. Das,et al. DNA methylation and cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] Gabrielle T Belz,et al. Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity , 2004, Nature Immunology.
[83] Mathew J Garnett,et al. Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.
[84] S. Wagner,et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. , 2004, The Journal of investigative dermatology.
[85] P. Kourilsky,et al. Foxp3 Expressing CD4+CD25high Regulatory T Cells Are Overrepresented in Human Metastatic Melanoma Lymph Nodes and Inhibit the Function of Infiltrating T Cells1 , 2004, The Journal of Immunology.
[86] G. Karczmar,et al. Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma , 2004, Clinical Cancer Research.
[87] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[88] M. Gore,et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] D. Lev,et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] J. Adams. The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.
[91] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[92] M. Weichenthal,et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] H. Pandha,et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers , 2004, British Journal of Cancer.
[94] M. Nosrati,et al. NF-κB in the Vascular Progression of Melanoma , 2004 .
[95] K. Sepkowitz,et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] J. Doroshow,et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. , 2004, Cancer.
[97] Gang Li,et al. The role of Bcl-2 family members in the progression of cutaneous melanoma , 2004, Clinical & Experimental Metastasis.
[98] C. Garbe,et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. , 2003, The Lancet. Oncology.
[99] J. Menell,et al. Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[100] D. Neuberg,et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[101] D. Lev,et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. , 2003, Molecular cancer therapeutics.
[102] M. Ranson,et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] V. Dragowska,et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[104] T. Gajewski,et al. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] L. Chin,et al. The INK4a/ARF locus and melanoma , 2003, Oncogene.
[106] P. Gibbs,et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. , 2003, Cancer immunity.
[107] M. Dolan,et al. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[108] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[109] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[110] J. Kirkwood,et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] G. Zhu,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[112] A. Blum,et al. Epidemiology of Cutaneous Melanoma in Germany and Worldwide , 2001, Skin Pharmacology and Physiology.
[113] L. Schuchter,et al. Metastatic melanoma , 2001, Current treatment options in oncology.
[114] A. Arance,et al. O6‐methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study , 2000, International journal of cancer.
[115] M. Atkins,et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[116] P. Lorigan,et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma , 2000, British Journal of Cancer.
[117] I. Frayling,et al. Desmoids in familial adenomatous polyposis are monoclonal proliferations , 2000, British journal of cancer.
[118] C. Boshoff,et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer , 2000, British Journal of Cancer.
[119] D. Schadendorf,et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] C. Begg,et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] R. Fisher,et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] J. Reed,et al. Expression of apoptosis regulators in cutaneous malignant melanoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[123] M. Atkins,et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[124] A. Hershko. THE UBIQUITIN SYSTEM FOR PROTEIN DEGRADATION , 1996 .
[125] J. Becker,et al. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. , 1996, The Journal of clinical investigation.
[126] S. Beissert,et al. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? , 1995, Immunology today.
[127] D. Crowther,et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. , 1994, British Journal of Cancer.
[128] M. Namer,et al. Final report of the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases , 1990, Cancer.